DALLAS, Aug. 17, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Avanir Pharmaceuticals (Nasdaq:AVNR). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Avanir Pharmaceuticals (Nasdaq:AVNR) should be of particular interest to biopharmaceutical companies: Bristol-Myers Squibb Co. (NYSE:BMY), Eli Lilly & Co. (NYSE:LLY), Amgen (Nasdaq:AMGN) and Gilead Sciences Inc. (Nasdaq:GILD).
It is available at: http://www.beaconequity.com/i/AVNR
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Avanir Pharmaceuticals (AVNR) engages in the development of therapeutic products for a variety of diseases primarily for the United States market. The Company has recently focused its resources to address the central nervous systems and inflammatory diseases markets.
In the report, the analyst notes:
"AVNR has one compound candidate, called Zenvia, in phase III clinical trials. Zanvia is developed to treat pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). ...If ultimately approved by the U.S. Food and Drug Administration (FDA), the market for AVNR's drug candidate Zenvia could reach $500 million to more than $1 billion at its market saturation. Zenvia is in phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following successful completion of this phase of development.
"On June 29, the Company announced that it has been added to the Russell 3000 Index as of June 26, 2009, following the Index's re-ranking of the 3,000 most capitalized stocks. The inclusion to the Russell 3,000 automatically includes AVNR into the small-cap Russell 2000 Index."
To read the entire report visit: http://www.beaconequity.com/i/AVNR
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions and information free of charge exclusively to individuals who wish to receive them.